A genetics‑guided drug, compound 6, targets CARD9 to subtly calm gut inflammation in Crohn’s disease, pointing to safer, longer‑lasting, precision treatments.
Institutional experiences with panitumumab monotherapy in metastatic colorectal cancer (mCRC) patients (pts) intolerant to cetuximab No significant financial relationships to disclose. This is an ASCO ...
The large intestine—which includes the cecum, colon, rectum, and anus—is a key part of the digestive system. It's a long, thin organ at the end of your digestive tract where your body produces and ...